Skip to main content

Table 2 Immunosuppressive/antiproliferative and vasoactive agents administered anytime during disease course in a multicentre systemic sclerosis cohort

From: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

 

Total (n = 497)

Diffuse (n = 243)

Limited (n = 254)

p

Immunosuppresives/ antiproliferatives

 Methotrexate

265 (53%)

134 (55%)

131 (52%)

NS

 Cyclophosphamide

130 (26%)

97 (40%)

33 (13%)

0.021

 Mycophenolate

58 (12%)

36 (15%)

22 (9%)

0.068

 Azathiorine

52 (10.5%)

27 (11%)

25 (10%)

NS

 Rituximab

43 (9%)

34 (14%)

9 (4%)

0.001

 Tocilizumab

25 (5%)

14 (6%)

11 (4%)

NS

Vasoactives

 Calcium channel blockers

338 (68%)

172 (71%)

166 (65%)

NS

 Bosentan

164 (33%)

104 (43%)

60 (24%)

0.001

 Abrisentan

13 (3%)

7 (3%)

6 (2%)

NS

 Macitentan

9 (2%)

3 (1%)

6 (2%)

NS

 Sildenafil

34 (7%)

23 (9%)

11 (4%)

0.05

 Iloprost

33 (7%)

18 (7%)

15 (6%)

NS

 Only immunosuppressive treatment

209 (42%)

96 (40%)

113 (45%)

NS

 Only vasoactive treatment

39 (8%)

20 (8%)

19 (7%)

NS

 Both treatments

156 (31%)

102 (42%)

54 (21%)

0.001

 No treatment

93 (19%)

25 (10%)

68 (27%)

0.001

  1. All data are shown as numbers (percentage)
  2. Mean disease duration: 11.8 ± 8.4 years, (mean + standard deviation)